AANEM News Express

AANEM News Express

Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series

2/3/2021
 
NSEB.jpgSubmitted by: Pritikanta Paul, MD
Edited by: Elliot Bodofsky, MD

Datta, et al. Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: A case series. Journal of Neuromuscular Diseases. 2020;7:269-277.

Summary: Eculizumab has been approved and used for AChR antibody positive myasthenia gravis but little is known about its efficacy for AChR seronegative cases. In this small retrospective study (N=6), treatment outcome with eculizumab for AChR negative patients was assessed. Clinically meaningful reductions (≥2 points) in total MG-ADL scores were observed before or at five months and were maintained to month twelve in all patients. There was also a reduction in the mean number of exacerbations per patient, before and after eculizumab initiation, respectively and no treatment related adverse effects.

Comments: There is preliminary evidence of a potential beneficial role of eculizumab in treatment refractory seronegative myasthenia gravis warranting larger randomized trials.
 


View Related News Stories:

  EducationScience News NSEB


Recent AANEM News

Science News: Serum Neurofilament Light Chain Predicts Long-Term Prognosis in Guillain-Barré Syndrome Patients

Latest Anthology of Articles from the News Science Editorial Board Now Available

Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series

President Biden’s Initial Health Care Priorities

Science News: Placebo Effect in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study and a Systematic Review





Advertisement

ABEM

Advertisement

Donate

Advertisement

SAE